Rational design of multi epitope-based subunit vaccine by exploring MERS-COV proteome: Reverse vaccinology and molecular docking approach.
Rational design of multi epitope-based subunit vaccine by exploring MERS-COV proteome: Reverse vaccinology and molecular docking approach.
复制标题
通过探索MERS-COV蛋白质组的基于多表位亚基疫苗的合理设计：反疫苗学和分子对接方法。
DOI：
10.1371/journal.pone.0245072
复制
发表时间：
2021
期刊：
影响因子：
3.7
通讯作者：
Khurshid M
中科院分区：
文献类型：
--
作者：
Ashfaq UA;Saleem S;Masoud MS;Ahmad M;Nahid N;Bhatti R;Almatroudi A;Khurshid M
中东呼吸综合征（MERS-COV）首先在沙特阿拉伯发现，是由一种新型冠状病毒引起的。世界不同地区，特别是韩国和中东，都有暴发记录，死亡率为35%。MERS-COV是一种单链阳性RNA病毒，通过与二肽基肽的受体结合到达宿主。由于缺乏有效的MERS-COV疫苗，因此建议通过快速发现病例、隔离、预防感染来对抗MERS-COV感染。因此，MERS-COV感染的治疗疫苗亟待开发。预防MERS-CoV感染的一种可能的抗病毒机制被认为是引起独特T细胞应答的MERS-CoV疫苗。在本研究中，我们结合分子对接和免疫信息学的方法来引入针对MERS-CoV的多表位疫苗（MEP），通过从7种病毒蛋白中选择15个保守表位，如3种结构蛋白（包膜蛋白、膜蛋白和核蛋白）和4种非结构蛋白（ORF 1a、ORF 8、ORF 3、ORF 4a）。根据T细胞、B细胞和IFN-γ表位之间的保守性选择表位，检查其与宿主的非同源性和抗原性。然后通过AAY接头将选择的表位连接至N末端的佐剂（β-防御素）以增加免疫原性潜力。将结构建模和理化特性应用于所开发的疫苗构建体。随后，该结构已成功对接抗原受体，Toll样受体3（TLR-3）和电子克隆，确保其表达效率是合法的。尽管如此，MEP需要测试来验证其安全性和免疫原性。
Middle East respiratory syndrome (MERS-COV), first identified in Saudi Arabia, was caused by a novel strain of coronavirus. Outbreaks were recorded from different regions of the world, especially South Korea and the Middle East, and were correlated with a 35% mortality rate. MERS-COV is a single-stranded, positive RNA virus that reaches the host by binding to the receptor of dipeptidyl-peptides. Because of the unavailability of the vaccine available for the protection from MERS-COV infection, the rapid case detection, isolation, infection prevention has been recommended to combat MERS-COV infection. So, vaccines for the treatment of MERS-COV infection need to be developed urgently. A possible antiviral mechanism for preventing MERS-CoV infection has been considered to be MERS-CoV vaccines that elicit unique T-cell responses. In the present study, we incorporated both molecular docking and immunoinformatic approach to introduce a multiepitope vaccine (MEP) against MERS-CoV by selecting 15 conserved epitopes from seven viral proteins such as three structural proteins (envelope, membrane, and nucleoprotein) and four non-structural proteins (ORF1a, ORF8, ORF3, ORF4a). The epitopes, which were examined for non-homologous to host and antigenicity, were selected on the basis of conservation between T-cell, B-cell, and IFN-γ epitopes. The selected epitopes were then connected to the adjuvant (β-defensin) at the N-terminal through an AAY linker to increase the immunogenic potential. Structural modelling and physiochemical characteristic were applied to the vaccine construct developed. Afterwards the structure has been successfully docked with antigenic receptor, Toll-like receptor 3 (TLR-3) and in-silico cloning ensures that its expression efficiency is legitimate. Nonetheless the MEP presented needs tests to verify its safety and immunogenic profile.
登录
查看更多内容
影响因子：
2.2
作者：
Ashfaq, Usman Ali;Ahmed, Bilal
通讯作者：
Ahmed, Bilal
影响因子：
8
作者：
COLOVOS, C;YEATES, TO
通讯作者：
YEATES, TO
影响因子：
2.9
作者：
BJELLQVIST, B;HUGHES, GJ;HOCHSTRASSER, D
通讯作者：
HOCHSTRASSER, D
影响因子：
3.2
作者：
Hajighahramani, Nasim;Nezafat, Navid;Ghasemi, Younes
通讯作者：
Ghasemi, Younes
DOI：
10.1093/protein/14.8.529
发表时间：
2001-08-01
期刊：
PROTEIN ENGINEERING
影响因子：
--
作者：
Arai, R;Ueda, H;Nagamune, T
通讯作者：
Nagamune, T